F2G
F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into chemistry-driven discovery. They have also assembled an experienced development capacity.
F2G
Industry:
Biotechnology Genetics Health Care Medical Pharmaceutical
Founded:
1998-01-01
Address:
Manchester, Manchester, United Kingdom
Country:
United Kingdom
Website Url:
http://www.f2g.com
Total Employee:
251+
Status:
Active
Contact:
44 (0)161 785 1270
Email Addresses:
[email protected]
Total Funding:
283.32 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apache Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Aprea
Aprea is a biopharmaceutical company that develops novel cancer therapeutics.
Aptahem
Aptahem develops aptamer-based drugs for the treatment of acute life-threatening conditions
Aptarion biotech
Aptarion biotech is a developer Biostable L-Aptamers for the treatment Of Life-Threatening diseases And for Biosensors.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Editas Medicine
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.
Forendo Pharma
Forendo Pharma is a developer of novel drugs intended for the treatment of urological and other endocrinological diseases.
GenSight Biologics
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.
Insilico Medicine
Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases.
ISCA Diagnostics
ISCA Diagnostics is specialising in point-of-care tests for life-threatening fungal infections of humans.
LYSOGENE
Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative disorders.
Methuselah Health
Methuselah Health identifies novel targets for treatment of ageing-related diseases.
NMD Pharma
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
RespiVert
Respivert is a small molecule drug discovery company for the treatment of chronic obstructive pulmonary diseases.
Travere Therapeutics
Travere discovers and develops drugs for the treatment of catastrophic diseases that are debilitating and often life-threatening.
SkinJect
SkinJect develops a novel drug delivery system for the treatment of non-melanoma skin cancers.
Smart Cells
Smart Cells provides stored stem cell units for use in the treatment of children with life-threatening illnesses.
TopoTarget UK Limited
TopoTarget UK Limited is discovers and develops drugs for the treatment of proliferative diseases.
Vical
Vical develops biopharmaceutical drugs to prevent and treat chronic or life-threatening infectious diseases.
ZS Pharma
ZS Pharma develops ion trap therapies for the treatment of life-threatening medical conditions such as hyperkalemia and liver diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Forbion Capital Partners
Forbion Capital Partners investment in Private Equity Round - F2G
Sofinnova Partners
Sofinnova Partners investment in Private Equity Round - F2G
Brace Pharma
Brace Pharma investment in Private Equity Round - F2G
Morningside Venture Investments
Morningside Venture Investments investment in Private Equity Round - F2G
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Private Equity Round - F2G
Novo Ventures
Novo Ventures investment in Private Equity Round - F2G
Advent Life Sciences
Advent Life Sciences investment in Private Equity Round - F2G
European Investment Bank
European Investment Bank investment in Debt Financing - F2G
Sectoral Asset Management
Sectoral Asset Management investment in Private Equity Round - F2G
Aisling Capital
Aisling Capital investment in Private Equity Round - F2G
Official Site Inspections
http://www.f2g.com Semrush global rank: 9.53 M Semrush visits lastest month: 141
- Host name: f2gcorp.tempurl.host
- IP address: 136.244.82.232
- Location: Frankfurt am Main Germany
- Latitude: 50.1103
- Longitude: 8.7147
- Timezone: Europe/Berlin
- Postal: 60314
More informations about "F2G"
Novel Therapeutics for Rare Fungal Infections | F2G
F2G Ltd – Registered Number 03578625 Lankro Way, Eccles Manchester, M30 0LX United Kingdom This site is intended for UK residents and is governed by UK laws and government regulations. F2G Ltd – Registered Number 03578625.See details»
F2G - Crunchbase Company Profile & Funding
F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that …See details»
We’re Fighting the Fungal Infection Crisis - F2G
In 2022, the World Health Organization (WHO) released a Fungal Priority Pathogens List (FPPL) based on antifungal resistance, deaths, annual incidence, and other clinical factors. 1 Our team aims to target some of the fungi on the …See details»
F2G - LinkedIn
F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections.See details»
F2G Company Profile 2024: Valuation, Funding & Investors
F2G General Information Description. Developer of a biotech drug designed to treat novel therapies for life-threatening fungal infections. The company's drug targets difficult-to-treat …See details»
Fighting the rising tide of antifungal resistance: a …
F2G’s lead orotomide candidate, olorofim, has been shown to be effective in vitro against phylogenetically clustered species of molds that cause infections in humans, including Aspergillus ...See details»
F2G - Funding, Financials, Valuation & Investors - Crunchbase
F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. ... How much …See details»
Francesco Maria Lavino appointed Chief Executive Officer of F2G Ltd
Apr 12, 2021 Francesco Maria Lavino, CEO of F2G Ltd, commented: “This is a transformational time to join F2G and I am very excited to lead the Company through its next phase of growth …See details»
Francesco Maria Lavino appointed Chief Executive Officer of F2G Ltd
Apr 12, 2021 Francesco Maria Lavino, CEO of F2G Ltd, commented: "This is a transformational time to join F2G and I am very excited to lead the Company through its next phase of growth …See details»
Corporate Governance - F2G
F2G is committed to supporting an environment where open, honest communication is the expectation and not the exception. The F2G Compliance Hotline offers employees, business …See details»
F2G Company Profile - Office Locations, Competitors, Revenue
F2G is an established UK Biotech focusing on the discovery and development of novel drugs to treat life threatening fungal diseases. Fungal infection typically affects the immune …See details»
F2G Announces $100 Million Financing to Advance Late-Stage …
Sep 12, 2024 MANCHESTER, United Kingdom, September 12, 2024 – F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to …See details»
F2G - Contacts, Employees, Board Members, Advisors & Alumni
F2G has 8 current employee profiles, including Chief Executive Officer Ian Nicholson. F2G has 9 board members and advisors, including Nanna Lüneborg . ContactsSee details»
F2G raises $100M for 2nd attempt to get new antifungal to market
Sep 12, 2024 After F2G’s first attempt to get a brand-new class of antifungal to market was derailed by the FDA, the U.K.-based biotech has secured $100 million in fresh funding to …See details»
Francesco Maria Lavino appointed Chief Executive Officer of F2G Ltd
Apr 12, 2021 Francesco Maria Lavino, CEO of F2G Ltd, commented: "This is a transformational time to join F2G and I am very excited to lead the Company through its next phase of growth …See details»
F2G Announces $100 Million Financing to Advance Late-Stage
Sep 12, 2024 F2G is a clinical-stage biopharmaceutical company with operations in the UK, US, and Austria focused on the discovery and development of novel therapies to treat potentially …See details»
F2G — Sofinnova Partners
F2G announces $100 million financing to advance late-stage development and commercialization of novel antifungal drug candidate Olorofim in the US; 15 June, 2023 F2G receives complete …See details»
We’re Driving Innovation in Antifungal Therapeutics - F2G
F2G’s first candidate is the first antifungal agent to be awarded Breakthrough Therapy Designation by the FDA for the indication of treatment of invasive fungal infections in patients …See details»
A Scientific Breakthrough in Antifungal Treatments | F2G
Combining our expertise in fungal molecular biology and biochemistry, we identify and develop novel antifungal compounds. Our team discovered the orotomides, a class of small-molecule …See details»
The Latest on Our Antifungal Breakthroughs - F2G
Sep 12, 2024 US-F2G-23-0003 01/24. Scroll to Top. We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking …See details»